Trial Profile
Phase I/II Trial of OSI-906 in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Ductal Adenocarcinoma of the Pancreas
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jun 2013
Price :
$35
*
At a glance
- Drugs Linsitinib (Primary) ; Erlotinib; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Jun 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 22 May 2012 New trial record